Looij B J, Roelfsema F, Frölich M
Department of Endocrinology, University Hospital, Leiden, The Netherlands.
Clin Endocrinol (Oxf). 1989 Nov;31(5):573-9. doi: 10.1111/j.1365-2265.1989.tb01281.x.
To determine whether human calcitonin inhibits GH secretion in acromegaly, as previously described for healthy subjects, the effect of an i.v. bolus injection of calcitonin or saline on GH levels in patients with active acromegaly was studied and compared to that of an i.v. bolus injection of the synthetic somatostatin analogue, octreotide. After the injection of calcitonin, GH levels decreased by 46% of initial values, whereas octreotide reduced GH levels by 87% and saline had no significant effect. Administration of calcitonin to acromegalics did not cause the transient rise in plasma PRL and TSH levels seen in normal subjects. Octreotide induced a decrease in plasma PRL in three out of seven patients. It is concluded that human calcitonin suppresses GH secretion in acromegaly, but not to normal levels; moreover the effect is less than that found for octreotide. In addition, acromegalic patients did not exhibit the PRL and TSH-releasing activity of calcitonin found in normal subjects, while octreotide inhibited PRL secretion in some acromegalic patients.
为了确定人降钙素是否如先前在健康受试者中所描述的那样抑制肢端肥大症患者的生长激素（GH）分泌，我们研究了静脉推注降钙素或生理盐水对活动期肢端肥大症患者GH水平的影响，并将其与静脉推注合成生长抑素类似物奥曲肽的效果进行比较。注射降钙素后，GH水平下降至初始值的46%，而奥曲肽使GH水平下降了87%，生理盐水则无显著影响。给肢端肥大症患者注射降钙素不会引起正常受试者中出现的血浆催乳素（PRL）和促甲状腺激素（TSH）水平的短暂升高。奥曲肽使7名患者中的3名血浆PRL水平降低。结论是人降钙素可抑制肢端肥大症患者的GH分泌，但不能降至正常水平；此外，其效果小于奥曲肽。此外，肢端肥大症患者未表现出正常受试者中发现的降钙素的PRL和TSH释放活性，而奥曲肽在一些肢端肥大症患者中抑制了PRL分泌。
